Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972135 · ClinicalTrials.gov registry record · Phase 2
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by SCRI Development Innovations.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 17
- Study locations
NCT05972135: Recruiting Phase 2 study of Multiple Myeloma, sponsored by SCRI Development Innovations.
NCT05972135 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by SCRI Development Innovations. The registered enrollment target is 100 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05972135, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by SCRI Development Innovations.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Primary Outcome
Evaluate the overall incidence of CRS in the first 2 cycles after a single dose of prophylactic tocilizumab given 2 to 4 hours prior to step-up dose 1 of teclistamab or talquetamab or after 3 doses of oral dexamethasone given after each step-up dose and the first full dose of teclistamab.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Talquetamab
- DRUG Tocilizumab
- DRUG Oral Dexamethasone
Study Locations (17)
Texas
- Texas Oncology - Austin
- Texas Oncology - San Antonio - San Antonio
- Texas Oncology - Northeast Texas - Tyler
Colorado
- Colorado Blood Cancer Institute - Denver
- Rocky Mountain Cancer Center - Denver
Tennessee
- TriStar Bone Marrow Transplant - Nashville
- Vanderbilt- Ingram Cancer Center - Nashville
Virginia
- Virginia Cancer Specialists - Fairfax
- Blue Ridge Cancer Center - Roanoke
Arizona
- Arizona Oncology Associates - Tucson
Delaware
- Medical Oncology Hematology Consultants - Newark
Florida
- Florida Cancer Specialists - Lake Mary
Maryland
- Maryland Oncology Hematology - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
What NCT05972135 shows while recruiting
NCT05972135 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Teclistamab is the first listed.
NCT05972135 lists 17 locations in 12 states (Texas, Colorado, Tennessee).
Frequently Asked Questions
What is clinical trial NCT05972135 about?
NCT05972135 is a clinical study titled "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma". This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
What is the current status of trial NCT05972135?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-10-23. Estimated completion is 2027-10.
What conditions does trial NCT05972135 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05972135?
The interventions under investigation include: Teclistamab (DRUG), Talquetamab (DRUG), Tocilizumab (DRUG), Oral Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT05972135?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05972135 being conducted?
This trial has 17 study locations across Arizona, Colorado, Delaware, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05972135's enrollment target sits among peer trials
100 165th of 438 higher than 262 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI